Takeda Says Type 2 Diabetes Drug On Track For 2015 Marketing
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical said its TAK-875, a GPR40 agonist for treating type 2 diabetes, is on a track for the U.S. market as early as 2015 and Europe the following year.